News

Reporting Quality of Life Outcomes Infrequent in Immunosuppression Trials

Quality-of-life (QoL) outcomes are important in informing patient-centered care, and should be reported in clinical trials in cases where treatments have adverse outcomes that may affect patient experience and well-being. For patients undergoing kidney transplantation, lifelong immunosuppression to maintain optimal transplant function. Immunosuppression drugs have a range of side-effect profiles, affect QOL, and increase the patient’s risk for serious adverse ... Read More »

Once-Daily Extended Release Tacrolimus Noninferior to Twice-Daily Formation

The most commonly used immunosuppressant in kidney transplantation patients is tacrolimus; it is used both early post-transplantation and as part of long-term maintenance regimens. However, according to researchers, tacrolimus has some limitations, including a narrow therapeutic window that requires drug monitoring and individual dose titration, inter-individual variation in absorption, and low bioavailablity of the immediate-release tacrolimus (IR-Tac) twice-daily capsule formation. ... Read More »

July/August 2016: Abstract Roundup

Acute Kidney Injury Postoperative Incident AKI with TAVR versus SAVR Journal of American Society of Nephrology. 27(61):1854-1860 For patients with symptomatic severe aortic stenosis who are at high risk for perioperative mortality, transcatheter aortic valve replacement (TAVR) offers an alternative to surgical aortic valve replacement (SAVR). Results of previous studies have demonstrated increased risk of postoperative acute kidney injury (AKI) ... Read More »

Immunosuppressive Therapy in Patients with IgA Nephropathy

The most common form of glomerulonephritis is IgA nephropathy. Previous studies have demonstrated the efficacy of immunosuppressive therapy to target mesangial IgA deposits and circulating IgA autoantibodies for the treatment of IgA nephropathy. In patients who have proteinuria with urinary protein excretion of >1 g per day, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend treatment with a blocker ... Read More »

Febuxostat Slows Decline in eGFR in Stages 3 and 4 CKD

Researchers in India recently conducted a study to test the hypothesis that febuxostat might slow the progression of kidney disease in patients with chronic kidney disease (CKD) and hyperuricemia. Febuxostat is a xanthine oxidase inhibitor that has been shown to have efficacy in treating hyperuricemia and gout. In patients with kidney failure, febuxostat does not require dose modification. CKD is ... Read More »

Meta-Analysis Assesses Accuracy of Kidney Failure Risk Equations

There is a worldwide increase in the incidence and prevalence of chronic kidney disease (CKD). There is variation among patients with CKD in rates of progression to kidney failure, depending on the severity of CKD, comorbid conditions, and the risk of dying prior to kidney failure. Interventions to slow progress of the disease would ideally be recommended for those patients ... Read More »

Comorbidities and Poorer Survival in Patients with Moderate CKD

The prevalence of chronic kidney disease (CKD) increases with age, making it likely that patients with CKD have multiple comorbid conditions, including hypertension, diabetes, and cardiovascular disease. Comorbidites may have an impact of the treatment burden, medication management, quality of life, and patient survival. Previous studies have included comorbidities in analyses of dialysis populations and comorbidities have been included in ... Read More »

Once-Daily Extended Release Tacrolimus Noninferior to Twice-Daily Formation

The most commonly used immunosuppressant in kidney transplantation patients is tacrolimus; it is used both early post-transplantation and as part of long-term maintenance regimens. However, according to researchers, tacrolimus has some limitations, including a narrow therapeutic window that requires drug monitoring and individual dose titration, inter-individual variation in absorption, and low bioavailablity of the immediate-release tacrolimus (IR-Tac) twice-daily capsule formation. ... Read More »

Survival Benefit with Transplants from Incompatible Live Donors

A recent multicenter study validated single-center evidence that patients who received kidney transplants from HLA-incompatible love donors had a substantial survival benefit compared with patients who did not undergo transplantation and those who waited for a kidney from a deceased donor. Babak J. Orandi, MD, R.A. Montgomery, MD, Dorry L. Segev, MD, and colleagues reported results of the 22-center study ... Read More »

Patient Perspectives on Self-Management Following Transplantation

Patients undergoing kidney transplantation experience better outcomes than those receiving maintenance hemodialysis. However, kidney transplant recipients must adhere to a complex and ongoing self-managed therapy regimen. Lack of adherence to medication regimen required following transplantation is the primary reason for transplant loss. Further, inadequate self-management undermines the benefits of transplantation and affects other health outcomes. Previous studies have demonstrated a ... Read More »